Abstract:Objective: Review the studies that investigate the mechanisms underlying imatinib-resistant gastrointestinal stromal tumors (GIST). Background: GIST are the most common mesenchymal tumors of the gastrointestinal (GI) tract and the most common sarcoma in humans. GIST are thought to be arise from interstitial cells of Cajal (ICC), pacemaker and neuromodulator cells in the GI tract, as well as "fibroblast"-like cells, which are another type of interstitial cells of the gut wall and also known as telocyte or platelet-derived growth factor-alpha (PDGFRA)-positive cells. The majority of GIST harbor gain-of-function mutations in either KIT or PDGFRA, and these gain-of-function mutations are mutually exclusive and most often heterozygous. GIST are responsive to the KIT/PDGFRA tyrosine kinase inhibitor (TKI), imatinib, the standard first-line drug for advanced and metastatic GIST. However, imatinib alone does not eradicate GIST despite an initial clinical benefit, and more than 90% of GIST harbor imatinib-resistance. Although second and third-generation TKIs have been developed and are currently in clinical use, they are not curative for refractory and metastatic GIST due to the emergence of clones with drug-resistant mutations. Eradication of drug-resistant GIST will cure patients with refractory GIST. Several mechanisms may contribute to refractory GIST. These mechanisms are secondary mutations in KIT and/or PDGFRA, alternative activation of tyrosine kinases, stem cells for GIST and cellular quiescence, a reversible nonproliferating state in which cells retain the ability to reenter cell proliferation. Methods: We review our current optimal treatment approach for managing patients with advanced and refractory GIST. Conclusions: This review explores the novel and potential therapeutic approaches to combat drug-resistant GIST.

The current state of chemotherapy for the treatment of gastrointestinal stromal tumors with different genotypes: a narrative review

An update on molecular genetics and drug resistance of gastrointestinal stromal tumors

Endoscopic Treatment Can Be a Viable Therapeutic Option for Esophageal Gastrointestinal Stromal Tumors

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges

Molecular characteristics and immune microenvironment of gastrointestinal stromal tumours: targets for therapeutic strategies

A narrative review of imatinib-resistant gastrointestinal stromal tumors

New Developments in Gastrointestinal Stromal Tumor

Some Hot Spots in the Treatment of Gastrointestinal Stromal Tumor

Advances of endoscopic and surgical management in gastrointestinal stromal tumors

Molecular Classification and Targeted Therapy of Gastrointestinal Stromal Tumors

Current Drug Resistance Mechanisms and Treatment Options in Gastrointestinal Stromal Tumors: Summary and Update

Advances in Drug Therapy for Gastrointestinal Stromal Tumour

[Treatment Progress of Gastrointestinal Stromal Tumor].

The management of metastatic GIST: current standard and investigational therapeutics

Gene Mutations in Gastrointestinal Stromal Tumors: Advances in Treatment and Mechanism Research

[The Shift of the Treatment Strategy of Gastrointestinal Stromal Tumor from the Surgical Perspective].

Precision Oncology in Gastrointestinal Stromal Tumors

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)